This review explores the cardiovascular consequences of opioids and the contributions of off-target electrophysiologic properties to mortality, and provides practical safety recommendations.
The researchers studied mothers of infants with neonatal abstinence syndrome and/or prenatal substance exposure and whether they received treatment for substance use disorder.
If immediate-release and extended-release formulations of buprenorphine are similarly efficacious to treat opioid use disorder, is one superior?
The researchers’ objective was to compare the patient satisfaction of adult outpatients with opioid dependence who were administered buprenorphine subcutaneously by depot vs those given the drug sublingually.
In a 1:1:1 ratio, patients were randomly assigned to receive a drug disposal kit and fact sheet, fact sheet alone, or no additional items when filling their opioid prescription.
The objective of this study was to describe differences between patients with chronic noncancer pain who could stop using chronic opioid analgesic therapy and those who exhibited refractory COAT reliance.
Most PPAs in prescribers’ practices focused on rules and consequences of noncompliance instead of on a shared treatment plan.
The authors propose evaluating which aspects of previous policy and practices for OUD should resume and which aspects of current policy and practice exemptions should continue.
The number of individuals filling buprenorphine prescriptions for OUD has plateaued but not decreased during the COVID-19 pandemic.
Walmart is being sued by the US Justice Department for its alleged role in the nation’s opioid crisis.
